RNS Number : 5375L
OKYO Pharma Limited
03 January 2023
 

OKYO PHARMA LIMITED

("OKYO" or "the Company")

 

Interim Results - availability

 

The OKYO Pharma Interim Report for the half-year ended 30 September 2022 (the "Interim Report") is available on the Company's website and can be found at: https://okyopharma.com/investors/corporate-governance/corporate-documents/.

A copy of the above document was submitted to the National Storage Mechanism and is available for inspection at: https://data.fca.org.uk/#/nsm/nationalstoragemechanism. 

 

Investor Relations Contact

LifeSci Advisors
(Investor Relations)

Irina Koffler
ikoffler@lifesciadvisors.com

+1-917-734-7387

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DOCEADFDEFFDEFA